ICU Medical (ICUI) – Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of ICU Medical (NASDAQ: ICUI) in the last few weeks:

• 3/27/2025 – ICU Medical was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
• 3/18/2025 – ICU Medical was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
• 3/12/2025 – ICU Medical was given a new $97.00 price target on by analysts at Raymond James.
• 3/12/2025 – ICU Medical was upgraded by analysts at Raymond James from an “outperform” rating to a “strong-buy” rating. They now have a $197.00 price target on the stock, down previously from $205.00.
• 3/10/2025 – ICU Medical was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.

ICU Medical Price Performance

ICU Medical stock opened at $144.28 on Friday. ICU Medical, Inc. has a 1 year low of $93.36 and a 1 year high of $196.26. The company has a debt-to-equity ratio of 0.75, a quick ratio of 1.03 and a current ratio of 2.29. The firm has a 50 day moving average price of $154.89 and a 200 day moving average price of $164.01. The company has a market cap of $3.54 billion, a price-to-earnings ratio of -31.57 and a beta of 0.73.

Insider Buying and Selling at ICU Medical

In other news, CEO Vivek Jain sold 1,373 shares of the firm’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $155.48, for a total value of $213,474.04. Following the transaction, the chief executive officer now directly owns 104,593 shares in the company, valued at $16,262,119.64. This trade represents a 1.30 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.70% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Vise Technologies Inc. lifted its holdings in shares of ICU Medical by 7.1% during the 4th quarter. Vise Technologies Inc. now owns 2,649 shares of the medical instruments supplier’s stock valued at $411,000 after acquiring an additional 176 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in ICU Medical by 20.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 51,531 shares of the medical instruments supplier’s stock valued at $7,996,000 after purchasing an additional 8,789 shares in the last quarter. Woodline Partners LP raised its position in ICU Medical by 4.5% in the fourth quarter. Woodline Partners LP now owns 122,239 shares of the medical instruments supplier’s stock valued at $18,968,000 after purchasing an additional 5,300 shares during the period. Squarepoint Ops LLC acquired a new position in shares of ICU Medical during the fourth quarter worth about $3,236,000. Finally, Tidal Investments LLC acquired a new stake in shares of ICU Medical in the fourth quarter valued at about $342,000. Hedge funds and other institutional investors own 96.10% of the company’s stock.

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.